title: [Clinical study on treatment of primary liver cancer by Aidi injection combined with cool-tip radiofrequency ablation].
abstract: OBJECTIVE
  To investigate the therapeutic efficacy and adverse reactions of Aidi Injection (AI) combined with percutaneous cool-tip radiofrequency ablation (CRFA) in treatment of primary liver cancer and to explore its effect on immune function.
  
  
  METHODS
  Eighty-nine patients with primary liver cancer at middle-late stage were assigned to the control group with CRFA alone and the treatment group treated with CRFA and intravenous dripping of AI 50 mL once every day for succesive 20 days.
  
  
  RESULTS
  Compared with those before treatment, the alanine aminotransferase (ALT) and albumin (ALB) levels showed no marked change, and CD4 subgroup of T lymphocyte and CD4/CD8 ratio elevated in the treatment group (P<0.01), while the ALT level elevated (P<0.05), ALB level decreased (P < 0.01), CD4 and CD4/CD8 ratio showed no change in the control group. The relapse rate was 20.0% (3/15) in patients with tumor more than 3 cm in diameter of the treatment group, which was obvious lower than that in the control group (55.0%, 11/20, P < 0.05).
  
  
  CONCLUSIONS
  AI treatment could relieve the impairment of CRFA on hepatic function, improve immune function and reduce relapse rate in patients with primary liver cancer.
authors.affiliation: Department of Oncology , Sir Run Shaw Hospital, Zhejiang University, Hangzhou. louhua33@yahoo.com.cn
authors.forename: Hai-Zhou
authors.initials: HZ
authors.lastname: Lou
authors.forename: Hong-Ming
authors.initials: HM
authors.lastname: Pan
authors.forename: Wei
authors.initials: W
authors.lastname: Jin
mesh_terms: D000328:Adult; D000368:Aged; D016516:CD4-CD8 Ratio; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000628:therapy*; D017115:Catheter Ablation / Q000379:methods*; D003131:Combined Modality Therapy; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008113:Liver Neoplasms / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D016896:Treatment Outcome
chemical_list: D004365:Drugs, Chinese Herbal; C517300:aidi herbal drug